Not Yet Enrolling

A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.

Trial Summary

Age Range
18 - 55 years
Conditions the trial is for
Multiple Sclerosis
What the trial is testing?
Pirtobruitinib
Could I receive a Placebo?
Yes
Enrollment Goal
200
Trial Dates
May 2024 - Feb 2026
How long will I be in the trial?
The study will last about 22 weeks and may include up to 9 visits.
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Have multiple sclerosis (MS)

  • Have at least 1 documented relapse within the previous year

  • Have at least 2 documented relapses within the last 2 years

Participants Must Not:

  • Had a diagnosis of primary progressive MS

  • Have history of another clinically significant neurological disease

  • Had a relapse of MS within 30 days prior to randomization

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources